BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) COO Xiaobin Wu sold 630 shares of the company's stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $250.87, for a total transaction of $158,048.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Xiaobin Wu also recently made the following trade(s):
- On Monday, June 16th, Xiaobin Wu sold 1,543 shares of BeOne Medicines stock. The shares were sold at an average price of $265.52, for a total transaction of $409,697.36.
- On Friday, June 6th, Xiaobin Wu sold 1,934 shares of BeOne Medicines stock. The stock was sold at an average price of $253.15, for a total value of $489,592.10.
- On Tuesday, April 1st, Xiaobin Wu sold 51,921 shares of BeOne Medicines stock. The stock was sold at an average price of $281.40, for a total value of $14,610,569.40.
BeOne Medicines Trading Down 2.3%
NASDAQ ONC traded down $5.70 during trading hours on Friday, hitting $247.08. 230,772 shares of the company's stock were exchanged, compared to its average volume of 298,435. The stock has a market cap of $27.07 billion, a price-to-earnings ratio of -66.42 and a beta of 0.30. The firm has a 50-day moving average of $245.59. The company has a current ratio of 1.96, a quick ratio of 1.71 and a debt-to-equity ratio of 0.05. BeOne Medicines Ltd. - Sponsored ADR has a 1-year low of $141.31 and a 1-year high of $287.88.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of ($0.71) by $1.93. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.12 billion. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. On average, sell-side analysts anticipate that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on ONC shares. Royal Bank Of Canada cut their target price on shares of BeOne Medicines from $312.00 to $311.00 and set an "outperform" rating for the company in a research note on Thursday, May 8th. JMP Securities set a $348.00 target price on BeOne Medicines in a research report on Friday, February 28th. Macquarie lifted their price objective on shares of BeOne Medicines from $259.00 to $313.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. JPMorgan Chase & Co. raised their price target on shares of BeOne Medicines from $311.00 to $317.00 and gave the company an "overweight" rating in a research note on Monday, April 21st. Finally, Sanford C. Bernstein set a $259.00 target price on BeOne Medicines in a report on Thursday, March 13th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, BeOne Medicines has an average rating of "Buy" and an average price target of $319.00.
View Our Latest Report on ONC
BeOne Medicines Company Profile
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Recommended Stories
Before you consider BeOne Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.
While BeOne Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
